# Distinct Symptoms, Cognition, and EEG Measures in First Episode Psychosis > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/first-episode-psychosis-distinct-symptoms-cannabis-impact/ > **Published:** 2026-06-25T12:15:46-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T16:58:58-04:00 > **Clinical Summary:** Explore first episode psychosis distinct symptoms linked to cannabis exposure, cognitive impairments, and EEG abnormalities in this clinical study summary. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. Mental HealthResearchNeurologyTHCSafetyAnxietyDosing Clinical Summary This study examines neurobiological differences between first-episode psychosis (FEP) patients with and without cannabis exposure, identifying distinct symptom profiles, cognitive impairments, and electroencephalogram abnormalities associated with cannabis-induced versus idiopathic psychosis. The findings suggest that cannabis exposure in FEP may produce a specific clinical phenotype with particular patterns of cognitive dysfunction and brain electrical activity, which could have implications for differential diagnosis and prognosis. Understanding these cannabis-specific neurobiological markers may help clinicians distinguish cannabis-related psychotic episodes from primary psychotic disorders, potentially informing treatment selection and predicting recovery trajectories. Since [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) is common in young populations at risk for first-episode psychosis, identifying these clinical and neurophysiological signatures could improve early identification and targeted intervention. Clinicians should conduct thorough substance use histories in FEP patients and consider whether observed cognitive and EEG patterns align with cannabis-related etiology, as this may influence medication selection, psychosocial treatment focus, and counseling regarding continued [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) during the critical early treatment phase. Clinical Perspective πŸ’­ This research examining neurocognitive and electrophysiological differences in cannabis-exposed first-episode psychosis patients adds nuance to an important clinical question, though several factors warrant careful interpretation. The distinction between cannabis as a precipitant versus an incidental exposure in vulnerable individuals remains difficult to establish in cross-sectional designs, and unmeasured confounders such as cannabis potency, frequency, route of administration, and concurrent substance use could substantially influence the observed EEG and cognitive patterns. Additionally, the heterogeneity of cannabis products and individual genetic susceptibility to [cannabinoid effects](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) means that findings from group-level analyses may not reliably predict individual patient trajectories. For clinicians evaluating a young patient presenting with first psychotic symptoms, this work reinforces the practical importance of obtaining detailed cannabis exposure history and considering abstinence or [harm reduction](https://cedclinic.com/can-you-mix-weed-and-alcohol/) as part of early intervention, while recognizing that psychotic illness in this population is multif πŸ’¬ Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan β†’](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion β†’](https://cedclinic.com/interact/discussion-forums/forum/mental-health/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20In%20a%20First%20Episode%20of%20Psychosis%20%28FEP%29%2C%20Distinct%20Symptoms%2C%20Cognition%2C%20and%20EEG%20Measures%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D66693)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D66693)[πŸ¦… Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20In%20a%20First%20Episode%20of%20Psychosis%20%28FEP%29%2C%20Distinct%20Symptoms%2C%20Cognition%2C%20and%20EEG%20Measures%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D66693)[πŸ“· Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[πŸ“ Read more on Substack](https://doctorapprovedcannabis.substack.com/)[πŸ”” Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Psychosis and Cannabis Legalization: Where’s the Evidence? | MedPage Today](https://cedclinic.com/psychosis-and-cannabis-legalization-wheres-the-evidence-medpage-today/) - [Genetic Link Between Cannabis Use and Psychosis Could Help Identify Those Most at Risk](https://cedclinic.com/genetic-risk-cannabis-psychosis-identify-high-risk-patients/) - [https://cedclinic.com/cannabis-use-disorder-psychiatric-risk/](https://cedclinic.com/cannabis-use-disorder-psychiatric-risk/) πŸ“° Source: [https://bbrfoundation.org/content/first-episode-psychosis-fep-distinct-symptoms-cognition-and-eeg-measures-seen-cannabis](https://bbrfoundation.org/content/first-episode-psychosis-fep-distinct-symptoms-cognition-and-eeg-measures-seen-cannabis) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Brain glutamate changes could link cannabis use to a higher risk of psychosis](https://cedclinic.com/brain-glutamate-changes-could-link-cannabis-use-to-a-higher-risk-of-psychosis/) This article explores how brain glutamate alterations may connect [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) with increased psychosis risk. [Read More](https://cedclinic.com/brain-glutamate-changes-could-link-cannabis-use-to-a-higher-risk-of-psychosis/) [Researchers Identify Genetic Pathways Linking Cannabis Use Disorder and Psychosis Risk](https://cedclinic.com/researchers-identify-genetic-pathways-linking-cannabis-use-disorder-and-psychosis-risk/) Discover genetic factors that may link [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) with heightened psychosis susceptibility. [Explore Study](https://cedclinic.com/researchers-identify-genetic-pathways-linking-cannabis-use-disorder-and-psychosis-risk/) [It may be legal for adults, but cannabis use a danger to young brains](https://cedclinic.com/it-may-be-legal-for-adults-but-cannabis-use-a-danger-to-young-brains/) Learn about the risks cannabis poses to [adolescent brain development](https://cedclinic.com/adolescent-cb1-receptor-antagonism-social-behavior/) despite adult legalization. [Learn More](https://cedclinic.com/it-may-be-legal-for-adults-but-cannabis-use-a-danger-to-young-brains/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR Β§ 164.514(b)) and criteria for secondary research exemption under 45 CFR Β§ 46.104(d)(4).